Company intelligence / Profile preview

Sichuan Yiaso Pharmaceutical Technology

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Sichuan Yiaso Pharmaceutical Technology is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company specializes in the development of oral incretin mimetics, including GLP-1, GIP, and glucagon receptor agonists, aimed at treating conditions such as type 2 diabetes and obesity. Yiaso leverages its expertise in medicinal chemistry to create differentiated candidates with improved bioavailability and patient compliance. Its lead programs are currently advancing through early-stage clinical trials in China.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Sichuan Yiaso Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Yiaso Pharmaceutical Technology.

Explore the full profile